Cas:71938-10-8 3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid manufacturer & supplier

Chemical Name:3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid

CAS.NO:71938-10-8

Synonyms:3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid

Molecular Formula:C₂₁H₁₆O₁₂

Molecular Weight:N/A

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:

Exact Mass:

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid Use and application,3(or 6)-Carboxy-9,10-dihydro-9,10-dioxo-1-anthracenyl beta-D-glucopyranosiduronic acid technical grade,usp/ep/jp grade.

Related News: These sites operate under cGMP conditions and have been inspected and approved by leading global pharmaceutical companies and regulatory authorities, including the US FDA. 4-chlorobutylphosphonic acid manufacturers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. 5,5-dioxido-2,3,3a,4-tetrahydro-1H-benzo[e]pyrrolo[2,1-c][1,2,4]thiadiazin-7-yl cyclopentanecarboxylate suppliers Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. diphenyl (4-propan-2-ylphenyl) phosphate vendor & factory In 2018, the Bengaluru-based Natural Capsules set up an R&D centre in at Attibele, Bengaluru. In 2020, when PLI scheme was announced it applied for the same. ,These sites operate under cGMP conditions and have been inspected and approved by leading global pharmaceutical companies and regulatory authorities, including the US FDA.